Dr. Ingo Langner

since 2005: Statistician / Epidemiologist
Leibniz Institute for Prevention Research and Epidemiology - BIPS (former: Bremen Institute for Prevention Research and Social Medicine, University of Bremen), Germany
till 2009: Department of Epidemiological Methods and Etiological
since 2010: Department of Clinical Epidemiology

2003 - 2004: Epidemiologist / Statistician
University of Bielefeld, Faculty of Public Health, Division of Epidemiology and Medical Statistics, Germany

2002 - 2003: Statistician
Ludwig-Maximilian-University Munich, SFB 386 ‚Statistical Analyses of Discrete Structures’, Germany

2000 - 2001:Epidemiologist / Statistician
University of Bielefeld, Faculty of Public Health, Division of Epidemiology and Medical Statistics, Germany

1999 - 2000: Senior-Statistician
Institute for Numerical Statistics, Department of Biometrics, Germany: statistical evaluation of clinical trials

1998 - 1999 : Fortbildung "Biometrie für Naturwissenschaftler"
MIBEG-Institute in Tübingen, Germany

1997 - 1998 : Statistician (professional)
Alfred Wegener Institute for Polar and Marine Research, Germany: (remittance work) Statistical evaluation of the results of a deap-see experiment concerning the effects of industrial manganese nodule mining on the biocoenosis of the benthos

1992 - 1997 : Scientific Assistant in the Ecosystem research of the Lower Saxonian Waddensea
Institute for Chemistry and Biology of the Marine Environment, Germany

1992 - 1997 : PhD-thesis, Biology
Institute for Chemistry and Biology of the Marine Environment
Carl von Ossietzky Universität Oldenburg, Germany

1984 – 1991: M.Sc. (equivalent), Biology
Carl von Ossietzky Universität Oldenburg, Germany

- Statistical Methods
- Developement and Valldation of Instruments and Algorithms in Secondary Data Analysis
- Epidemiology in Patient Populations
- Health Services Research
- Drug Utilization Research
- Cancer Epidemiology
- Radiation Epidemiology
- Occupational Epidemiology

    Selected BIPS-Publications

  • Articles with peer review

  • Heinig M, Schäfer W, Langner I, Zeeb H, Haug U. German mammography screening program: Adherence, characteristics of (non-)participants and utilization of non-screening mammography - A longitudinal analysis. BMC Public Health. 2023;23:1678.
  • Heinze F, Czwikla J, Heinig M, Langner I, Haug U. German mammography screening program: Program sensitivity between 2010 and 2016 estimated based on German health claims data. BMC Cancer. 2023;23:852.
  • Riedel O, Braitmaier M, Langner I. Dementia in health claims data: The influence of different case definitions on incidence and prevalence estimates. International Journal of Methods in Psychiatric Research. 2023;32(2):e1947.
  • Riedel O, Braitmaier M, Langner I. Stability of individual dementia diagnoses in routine care: Implications for epidemiological studies. Pharmacoepidemiology and Drug Safety. 2022;31(5):546-555.
  • Riedel O, Klau S, Langner I, Bachmann CJ, Scholle O. Prevalence of multimodal treatment in children and adolescents with ADHD in Germany: A nationwide study based on health insurance data. Child and Adolescent Psychiatry and Mental Health. 2021;15:76.
  • Langner I, Riedel O, Czwikla J, Heinze F, Rothgang H, Zeeb H, Haug U. Linkage of routine data to other data sources in Germany: A practical example illustrating challenges and solutions. Das Gesundheitswesen. 2020;82(Suppl. 2):S117-S121.
  • Czwikla J, Urbschat I, Kieschke J, Schüssler F, Langner I, Hoffmann F. Assessing and explaining geographic variations in mammography screening participation and breast cancer incidence. Frontiers in Oncology. 2019;9:909.
  • Langner I, Haug U, Scholle O, Lindemann C, Schröder C, Riedel O. Potential explanations for increasing methylphenidate use in children and adolescents with attention-deficit/hyperactivity disorder in Germany from 2004 to 2013. Journal of Clinical Psychopharmacology. 2019;39(1):39-45.
  • Langner I, Krieg V, Heidinger O, Hense H-W, Zeeb H. Anreicherung eines GKV-Datensatzes mit amtlichen Todesursachen über einen Abgleich mit dem Epidemiologischen Krebsregister Nordrhein-Westfalen: Machbarkeitsstudie und Methodenvergleich. Das Gesundheitswesen. 2019;81(8/9):629-635.
  • Langner I, Ohlmeier C, Haug U, Hense H-W, Czwikla J, Zeeb H. Implementation of an algorithm for the identification of breast cancer deaths in German health insurance claims data: A validation study based on a record linkage with administrative mortality data. BMJ Open. 2019;9:e026834.
  • Langner I, Ohlmeier C, Zeeb H, Haug U, Riedel O. Individual mortality information in the German Pharmacoepidemiological Research Database (GePaRD): A validation study using a record linkage with a large cancer registry. BMJ Open. 2019;9:e028223.
  • Lindemann C, Langner I, Banaschewski T, Garbe E, Mikolajczyk R. The risk of hospitalizations with injury diagnoses in a matched cohort of children and adolescents with and without attention deficit/hyperactivity disorder in Germany: A database study. Frontiers in Pediatrics. 2017;5:220.
  • Riedel O, Bitters D, Amann U, Garbe E, Langner I. Estimating the prevalence of Parkinson's disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data. International Journal of Geriatric Psychiatry. 2016;31(8):938-943.
  • Dörks M, Langner I, Timmer A, Garbe E. Treatment of paediatric epilepsy in Germany: Antiepileptic drug utilisation in children and adolescents with a focus on new antiepileptic drugs. Epilepsy Research. 2013;103(1):45-53.
  • Kraut A, Langner I, Lindemann C, Banaschewski T, Petermann U, Petermann F, Mikolajczyk R, Garbe E. Comorbidities in ADHD children treated with methylphenidate: A database study. BMC Psychiatry. 2013;13:11.
  • Langner I, Garbe E, Banaschewski T, Mikolajczyk R. Twin and sibling studies using health insurance data: The example of attention deficit/hyperactivity disorder (ADHD). PLOS ONE. 2013;8(4):e62177.
  • Garbe E, Mikolajczyk R, Banaschewski T, Petermann U, Petermann F, Kraut A, Langner I. Drug treatment patterns of attention deficit/hyperactivity disorder in children and adolescents in Germany: Results from a large population-based cohort study. Journal of Child and Adolescent Psychopharmacology. 2012;22(6):452-458.
  • Lindemann C, Langner I, Kraut A, Banaschewski T, Schad-Hansjosten T, Petermann U, Petermann F, Schreyer-Mehlhop I, Garbe E, Mikolajczyk R. Age-specific prevalence, incidence of new diagnoses and drug treatment of attention-deficit / hyperactivity disorder in Germany. Journal of Child and Adolescent Psychopharmacology. 2012;22(4):307-314.
  • Langner I, Schmeißer N, Mester B, Behrens T, Gottlieb A, Ahrens W. Case-control study of male germ cell tumors nested in a cohort of car manufacturing workers: Findings from the occupational history. American Journal of Industrial Medicine. 2010;53(10):1006-1018.
  • Zeeb H, Hammer GP, Langner I, Schafft T, Bennack S, Blettner M. Cancer mortality among German aircrew: second follow-up. Radiation and Environmental Biophysics. 2010;49(2):187-194.
  • Hammer GP, Fehringer F, Seitz G, Zeeb H, Dulon M, Langner I, Blettner M. Exposure and mortality in a cohort of German nuclear power workers. Radiation and Environmental Biophysics. 2008;47(1):95-99.
  • Articles without peer review

  • Kimmel A, Thomas S, Wagner A, Windeler J, Reif K, Langner I, Görres S. Grad der Selbständigkeit soll entscheiden: Neues Begutachtungsverfahren zur Feststellung von Pflegebedürftigkeit. Soziale Sicherheit. 2009;(1):22-26.
  • Posters at scientific meetings/conferences

  • Ohlmeier C, Schmedt N, Hillebrand K, Langner I, Mikolajczyk R, Garbe E. Validation of mortality information in the German Pharmacoepidemiological Research Database (GePaRD). 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 25-28 August 2013, Montreal, Canada.

For further publications please follow this link:

- Master of Science in Epidemiology (MSE), Bielefeld University
- Advanced epidemiological and statistical methods in cohort analysis and their realisation in SAS, Master SC Epidemiology, Bremen University

The responsibility for the content of this page lies with Ingo Langner.


+49 (0)421 218-56-867